IMMPHENTIV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Immphentiv, and when can generic versions of Immphentiv launch?
Immphentiv is a drug marketed by Hikma and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in IMMPHENTIV is phenylephrine hydrochloride. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Immphentiv
A generic version of IMMPHENTIV was approved as phenylephrine hydrochloride by HIKMA on December 20th, 2012.
Summary for IMMPHENTIV
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for IMMPHENTIV |
| DailyMed Link: | IMMPHENTIV at DailyMed |
Pharmacology for IMMPHENTIV
| Drug Class | alpha-1 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha1-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for IMMPHENTIV
US Patents and Regulatory Information for IMMPHENTIV
IMMPHENTIV is protected by two US patents.
Patents protecting IMMPHENTIV
Phenylephrine hydrochloride ready-to-use solution
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-004 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-005 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-004 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hikma | IMMPHENTIV | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 203826-005 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
